FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212535051> ?p ?o ?g. }

• W3212535051 endingPage "35" @default.
• W3212535051 startingPage "35" @default.
• W3212535051 abstract "Abstract Background: The standard of induction therapy for fit patients(pts) with acute myeloid leukemia (AML) has not changed much since 1973, when the 7+3 regimen of cytarabine and anthracycline was born. This combination of agents produces complete remission (CR) in about 60-80% of younger adults and in 40-60% of older adults (60 years) depending on genetic risk group. However, compared with AML in favorable- and intermediate-risk categories, induction therapy for fit AML pts in adverse-risk category had significantly lower CR rates and dismal outcome. Recently, combination therapy with venetoclax and azacitidine or decitabine for the treatment of older pts with de novo AML unsuitable for intensive chemotherapy, has resulted in response rates of 60-70%. Currently, the role of venetoclax in combination with azacitidine or decitabine in young adults with newly diagnosed ELN adverse-risk AML remains unclear. This study aims to evaluate the safety and efficacy of venetoclax plus decitabine as induction therapy in young adults with newly diagnosed ELN adverse-risk AML. Methods: This is an interim analysis of an ongoing phase 2 clinical trial (NCT04752527) of a planned 42 untreated ELN adverse-risk AML pts 18-59. The fast next-generation sequencing (NGS) for the most commonly mutated genes in AML using Oncomine TM myeloid research assay on Ion S5 and Chef platform (Thermo Fisher) was completed within 72 hours, which could screen for the ELN adverse-risk features in AML pts together with multiplex RT-PCR and fluorescence in situ hybridization (FISH). In cycle 1, pts receive decitabine 20mg/m 2 on d1-5 and venetoclax escalated from 100mg to 200mg to 400mg until 28-day cycle is finished. For pts with high FLT3-ITD allelic ratio, sorafenib was optional administered at a dose of 400mg orally twice daily. Bone marrow assessments were performed on d28 before subsequent cycle. Pts who achieve composite complete remission (defined as complete remission [CR], CR with incomplete hematologic recovery [CRi], CR with partial hematological recovery [CRh], and morphologic leukemia free state [MLFS]) receive 1 or 2 cycles of consolidation with high dose of cytarabine followed by allogeneic hematopoietic stem cell transplantation. Non-responders or pts who achieve partial remission (PR) receive 1 additional cycle of combination of venetoclax plus decitabine. The primary objective is to determine the composite complete remission rate (CR+CRi+CRh+MLFS). The endpoint is to show that venetoclax plus decitabine is superior to historical control (HC) of cytarabine combined with idarubicin (12 mg/m 2) in young adults with newly diagnosed ELN adverse-risk AML. Results: From February 1, 2021 to July 31, 2021, a total of 104 newly-diagnosed AML pts underwent screening, and 30 pts were classified as ELN adverse-risk category by NGS (within 72 hours) together with multiplex RT-PCR and FISH. Totally, 19 pts with ELN adverse-risk were enrolled, comprising 14 males and 5 females. 2 (10%) pts had secondary AML (sAML). Median age was 38 years (range, 19-57 years). The baseline patient characteristics are summarized in Table 1. Outcome data were updated as of July 2021, for a median follow-up of 2.7 months. Among 14 evaluable pts, 4 (28.6%) achieved a CR, 5 (35.7%) achieved a CRh and 5 (35.7%) had a PR in cycle 1. Individual pts data of this study (n = 14) was compared to a HC, combining individual pts data of AML with adverse-risk from the SZ3202 registry (n = 42) and the pts treated with IA (IDA:12 mg/m 2) in the same period (n = 18). The venetoclax plus decitabine cohort demonstrated higher rates of CR than the HC cohort, with an observed CR/CRh rate of 64.3%, compared with 38.3% (Figure 1). The regimen was well tolerated, with 4- and 8-week mortality rates of 0% and 0%, respectively. The most frequent nonhematologic adverse events of any grade were neutropenic fever (n=6) and pneumonia (n=3). With a median follow-up of 2.7 months, the median remission duration and overall survival (OS) have not been reached. Tumor lysis syndrome occurred in one patient and resolved with medical management. Conclusions: Preliminary results indicate that venetoclax plus decitabine is an effective, lower-intensity regimen that is well tolerated for young adults with newly diagnosed ELN adverse-risk AML, producing high rates of CR, low rates of infections, and low rates of early death. Recruitment of young adults with newly diagnosed ELN adverse-risk AML pts for this trial is ongoing. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3212535051 created "2021-11-22" @default.
• W3212535051 creator A5001850914 @default.
• W3212535051 creator A5006739024 @default.
• W3212535051 creator A5007504059 @default.
• W3212535051 creator A5016151156 @default.
• W3212535051 creator A5018863416 @default.
• W3212535051 creator A5022501218 @default.
• W3212535051 creator A5027819567 @default.
• W3212535051 creator A5030108757 @default.
• W3212535051 creator A5031641778 @default.
• W3212535051 creator A5042921774 @default.
• W3212535051 creator A5056394760 @default.
• W3212535051 creator A5057837748 @default.
• W3212535051 creator A5057883663 @default.
• W3212535051 creator A5068951778 @default.
• W3212535051 creator A5071443000 @default.
• W3212535051 creator A5089036668 @default.
• W3212535051 date "2021-11-05" @default.
• W3212535051 modified "2023-10-16" @default.
• W3212535051 title "Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial" @default.
• W3212535051 doi "https://doi.org/10.1182/blood-2021-153288" @default.
• W3212535051 hasPublicationYear "2021" @default.
• W3212535051 type Work @default.
• W3212535051 sameAs 3212535051 @default.
• W3212535051 citedByCount "4" @default.
• W3212535051 countsByYear W32125350512022 @default.
• W3212535051 countsByYear W32125350512023 @default.
• W3212535051 crossrefType "journal-article" @default.
• W3212535051 hasAuthorship W3212535051A5001850914 @default.
• W3212535051 hasAuthorship W3212535051A5006739024 @default.
• W3212535051 hasAuthorship W3212535051A5007504059 @default.
• W3212535051 hasAuthorship W3212535051A5016151156 @default.
• W3212535051 hasAuthorship W3212535051A5018863416 @default.
• W3212535051 hasAuthorship W3212535051A5022501218 @default.
• W3212535051 hasAuthorship W3212535051A5027819567 @default.
• W3212535051 hasAuthorship W3212535051A5030108757 @default.
• W3212535051 hasAuthorship W3212535051A5031641778 @default.
• W3212535051 hasAuthorship W3212535051A5042921774 @default.
• W3212535051 hasAuthorship W3212535051A5056394760 @default.
• W3212535051 hasAuthorship W3212535051A5057837748 @default.
• W3212535051 hasAuthorship W3212535051A5057883663 @default.
• W3212535051 hasAuthorship W3212535051A5068951778 @default.
• W3212535051 hasAuthorship W3212535051A5071443000 @default.
• W3212535051 hasAuthorship W3212535051A5089036668 @default.
• W3212535051 hasConcept C104317684 @default.
• W3212535051 hasConcept C126322002 @default.
• W3212535051 hasConcept C143998085 @default.
• W3212535051 hasConcept C150194340 @default.
• W3212535051 hasConcept C185592680 @default.
• W3212535051 hasConcept C190727270 @default.
• W3212535051 hasConcept C197934379 @default.
• W3212535051 hasConcept C2776239401 @default.
• W3212535051 hasConcept C2777938653 @default.
• W3212535051 hasConcept C2778041864 @default.
• W3212535051 hasConcept C2778461978 @default.
• W3212535051 hasConcept C2778729363 @default.
• W3212535051 hasConcept C2779675984 @default.
• W3212535051 hasConcept C2780235182 @default.
• W3212535051 hasConcept C2781413609 @default.
• W3212535051 hasConcept C535046627 @default.
• W3212535051 hasConcept C55493867 @default.
• W3212535051 hasConcept C61943457 @default.
• W3212535051 hasConcept C71924100 @default.
• W3212535051 hasConceptScore W3212535051C104317684 @default.
• W3212535051 hasConceptScore W3212535051C126322002 @default.
• W3212535051 hasConceptScore W3212535051C143998085 @default.
• W3212535051 hasConceptScore W3212535051C150194340 @default.
• W3212535051 hasConceptScore W3212535051C185592680 @default.
• W3212535051 hasConceptScore W3212535051C190727270 @default.
• W3212535051 hasConceptScore W3212535051C197934379 @default.
• W3212535051 hasConceptScore W3212535051C2776239401 @default.
• W3212535051 hasConceptScore W3212535051C2777938653 @default.
• W3212535051 hasConceptScore W3212535051C2778041864 @default.
• W3212535051 hasConceptScore W3212535051C2778461978 @default.
• W3212535051 hasConceptScore W3212535051C2778729363 @default.
• W3212535051 hasConceptScore W3212535051C2779675984 @default.
• W3212535051 hasConceptScore W3212535051C2780235182 @default.
• W3212535051 hasConceptScore W3212535051C2781413609 @default.
• W3212535051 hasConceptScore W3212535051C535046627 @default.
• W3212535051 hasConceptScore W3212535051C55493867 @default.
• W3212535051 hasConceptScore W3212535051C61943457 @default.
• W3212535051 hasConceptScore W3212535051C71924100 @default.
• W3212535051 hasIssue "Supplement 1" @default.
• W3212535051 hasLocation W32125350511 @default.
• W3212535051 hasOpenAccess W3212535051 @default.
• W3212535051 hasPrimaryLocation W32125350511 @default.
• W3212535051 hasRelatedWork W2889423049 @default.
• W3212535051 hasRelatedWork W3094888568 @default.
• W3212535051 hasRelatedWork W3129966379 @default.
• W3212535051 hasRelatedWork W3212535051 @default.
• W3212535051 hasRelatedWork W4206245401 @default.
• W3212535051 hasRelatedWork W4220981828 @default.
• W3212535051 hasRelatedWork W4224925603 @default.
• W3212535051 hasRelatedWork W4238265892 @default.
• W3212535051 hasRelatedWork W4312049268 @default.
• W3212535051 hasRelatedWork W4317476711 @default.
• W3212535051 hasVolume "138" @default.

• next